771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
oleh: Evan Hall, Adi Diab, Sajeve Thomas, Randy Sweis, Anthony El-Khoueiry, Naveen K Mehta, Jennifer S Michaelson, Laura Liu, Reham Abdel-Wahab, Jeffrey A Jones, Kaida Wu, Benjamin S Maciejewski
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.